aid: aavantgardebio
name: AAVantgarde Bio
description: >-
  AAVantgarde Bio is a clinical-stage biotechnology company headquartered in Milan,
  Italy, developing next-generation adeno-associated virus (AAV) gene therapies for
  inherited retinal diseases with high unmet need. Founded in 2021 by Prof. Alberto
  Auricchio, the company has built two proprietary vector platforms — dual hybrid and
  dual intein — that overcome the DNA cargo capacity limit of a single AAV vector by
  splitting a large expression cassette across two AAV8 vectors that recombine inside
  the target cell. Its lead programs are AAVB-081 for retinitis pigmentosa due to Usher
  syndrome type 1B (LUCE-1 Phase 1/2, the first dual AAV gene therapy tested clinically
  in an ocular indication) and AAVB-039 for ABCA4-associated Stargardt disease (CELESTE
  Phase 1/2), which holds FDA Fast Track and Orphan Drug designation. The company
  raised a EUR 61 million Series A and closed a USD 141 million Series B. AAVantgarde
  publishes no public API, developer program or machine-readable contract; this profile
  records what its public web surface actually serves.
url: https://raw.githubusercontent.com/api-evangelist/aavantgardebio/refs/heads/main/apis.yml
image: https://www.aavantgarde.com/assets/img/AavantgardeBio-logo.svg
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-2026-09-05
specificationVersion: '0.20'
created: '2026-09-05'
modified: '2026-09-05'
tags:
- Company
- Biotechnology
- Gene Therapy
- Life Sciences
- Pharmaceuticals
- Clinical Trials
- Ophthalmology
- Rare Disease
- Healthcare
- Italy
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: VulnerabilityDisclosure
  url: security/aavantgardebio-vulnerability-disclosure.yml
- type: Website
  url: https://www.aavantgarde.com/en/
- type: About
  url: https://www.aavantgarde.com/en/about/
- type: Blog
  url: https://www.aavantgarde.com/en/news/
- type: PrivacyPolicy
  url: https://www.aavantgarde.com/en/privacy-notice/
- type: LinkedIn
  url: https://www.linkedin.com/company/aavantgarde-bio
- type: WellKnown
  url: well-known/aavantgardebio-well-known.yml
- type: SecurityTxt
  url: well-known/aavantgardebio-security.txt
- type: Conformance
  url: conformance/aavantgardebio-conformance.yml
- type: DomainSecurity
  url: security/aavantgardebio-domain-security.yml
- type: LLMsTxt
  url: llms/aavantgardebio-llms.txt
x-enrichment:
  date: '2026-09-05'
  status: minimal
  artifacts_added: 8
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    AAVantgarde Bio is a clinical-stage gene therapy company whose product is an
    investigational AAV vector, not software — the corporate site has no developer
    section at all (nav is About / Innovation / Clinical Trials / For Patients / News /
    Careers / Contact), api., developer., docs., status. and trust. subdomains are all
    NXDOMAIN, there is no GitHub organization, and the only machine-readable documents
    the site serves are the OpenID discovery and JWKS files its Umbraco CMS emits for
    website-member sign-in.
  evidence:
    - url: https://www.aavantgarde.com/en/
      status: 200
    - url: https://www.aavantgarde.com/llms.txt
      status: 404
    - url: https://www.aavantgarde.com/.well-known/api-catalog
      status: 404
    - url: https://www.aavantgarde.com/.well-known/agent-card.json
      status: 404
    - url: https://www.aavantgarde.com/.well-known/openid-configuration
      status: 200
    - url: https://api.github.com/orgs/aavantgarde-bio
      status: 404
  checked: '2026-09-05'